With 1.03 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6946 whereas the lowest price it dropped to was $0.59. The 52-week range on TCBP shows that it touched its highest point at $26.80 and its lowest point at $0.35 during that stretch. It currently has a 1-year price target of $2.99. Beta for the stock currently stands at -0.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TCBP was up-trending over the past week, with a rise of 20.12%, but this was up by 27.55% over a month. Three-month performance dropped to -87.20% while six-month performance fell -91.66%. The stock lost -97.58% in the past year, while it has gained 17.44% so far this year.
Float and Shares Shorts:
On 2024-11-15, short shares totaled 38332.0, which was 670.0 higher than short shares on 1728950400. In addition to Mr. Bryan Leland Kobel as the firm’s CEO & Director, Mr. Martin Edward Thorp serves as its CFO & Director.
Institutional Ownership:
Through their ownership of 0.070149995 of TCBP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, TCBP reported revenue of $0.0 and operating income of -$2054751.0. The EBITDA in the recently reported quarter was -$1936559.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With TCBP analysts setting a high price target of 3.0 and a low target of 3.0, the average target price over the next 12 months is 3.0. Based on these targets, TCBP could surge 391.8% to reach the target high and rise by 391.8% to reach the target low. Reaching the average price target will result in a growth of 391.8% from current levels.
Analysts have provided yearly estimates in a range of -$9.9824643e-05 being high and -$9.9824643e-05 being low. For TCBP, this leads to a yearly average estimate of -$9.9824643e-05.
